Treatment with anti-ErbB2 antibodies

An antibody, receptor technology, applied in the treatment of diseases characterized by ErbB2 overexpression, can solve problems such as stimulating tumor growth

Inactive Publication Date: 2001-01-24
GENENTECH INC
View PDF24 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Different levels of tumor suppression were detected for the four ant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment with anti-ErbB2 antibodies
  • Treatment with anti-ErbB2 antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0154] Materials and methods

[0155] Anti-ErbB2 monoclonal antibody. Press Fendly and other Cancer Res. 50: 1550-1558 (1990) and WO89 / 06692, produced anti-ErbB2 IgG specific for the extracellular domain of ErbB2 1 κ mouse monoclonal antibody 4D5. In short, such as Hudziak et al., Proc. Natl. Acad. Sci. (USA) 84: 7159 (1987) produced NIH3T3 / HER2-3 400 Cells (each cell expresses approximately 1×10 5 ErbB 2 molecules), the cells were harvested with phosphate buffered saline (PBS) containing 25 mM EDTA for immunization of BALB / c mice. At 0, 2, 5, and 7 weeks, mice were injected intraperitoneally containing 10 7 0.5 ml of PBS for cells. In the 9th and 13th weeks, antiserum can immunoprecipitate 32 Mice with p-labeled ErbB2 were injected intraperitoneally with ErbB2 membrane extract purified by malt agglutinin-Sepharose (WGA). Then, 0.1 ml of ErbB2 preparation was injected intravenously, and spleen cells were fused with the mouse myeloma cell line X63-Ag8.653. The ErbB2 binding ability...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.

Description

Invention field [0001] The present invention relates to methods of treating diseases characterized by ErbB2 overexpression. More specifically, the present invention relates to the use of a combination of an anti-ErbB2 antibody and a chemotherapeutic agent instead of an anthracycline (anthracycline such as doxorubicin or epirubicin) to treat cancer patients who are susceptible to or diagnosed with overexpressing ErbB2. Background of the invention [0002] It has been determined that proto-oncogenes encoding growth factors and growth factor receptors play an important role in the pathogenesis of various human malignancies (including breast cancer). It has been found that the human ErbB2 gene (erbB2, also known as her2 or c-erbB-2), is overexpressed in about 25-30% of human breast cancer patients. This gene encodes an epidermal growth factor receptor (EGFR ) Related 185kd transmembrane glycoprotein receptor (p185 HER2 ) (Slamon et al., Science, 235: 177-182 [1987]; Slamon et al., Sc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/335A61K38/00C12N15/09A61K39/395A61K45/06A61P35/00A61P43/00C07K16/32C12P21/08
CPCA61K39/395A61K39/39558C07K16/32A61K31/7068A61K38/00A61K2039/505C07K2317/24A61K45/06A61K31/337A61P1/04A61P1/16A61P1/18A61P11/00A61P13/08A61P13/10A61P13/12A61P15/00A61P25/00A61P35/00A61P35/02A61P35/04A61P37/02A61P43/00A61K31/335A61K2300/00
Inventor S·谢克V·E·佩顿
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap